Scientists in Shanghai say some recovered patients show no signs of the neutralising proteins Early-stage findings could have implications for vaccine development and herd immunity, they say Researchers in Shanghai hope to determine whether some recovered coronavirus patients have a higher risk of reinfection after finding surprisingly low levels of Covid-19 antibodies in a number of people
In a paper just published on JAMA is reported a retrospective case series that involved 1591 critically ill patients admitted from February 20 to March 18, 2020. 99% (1287 of 1300 patients) required respiratory support, including endotracheal intubation in 88% and noninvasive ventilation in 11%; ICU mortality was 26%. Retrospective case series were referred for
A team of Chinese scientists has isolated several antibodies that it says are “extremely effective” at blocking the ability of the new coronavirus to enter cells, which eventually could be helpful in treating or preventing COVID-19. There is currently no proven effective treatment for the disease, which originated in China and is spreading across the
New research from USC Marshall and UC Riverside suggest models to answer that question. For Italy date of control is provided after April 14th. Amid the historic Covid-19 pandemic, questions about everything from medical supplies to the economy abound. But one question is uppermost in people’s minds: How long will stay-at-home restrictions need to continue
This report contains data on all confirmed COVID-19 cases reported to ICNARC up to midday on 03 April 2020 from critical care units participating in the Case Mix Programme (all NHS adult, general intensive care and combined intensive care/high dependency units inEngland, Wales and Northern Ireland, plus some specialist and non-NHS critical care units). Reporting
Paracetamol should be used in preference to non-steroidal anti-inflammatory drugs for managing fever in patients with suspected covid-19 until more evidence is available on the safety of NSAIDs, the National Institute for Health and Care Excellence advises in a rapid guideline on managing symptoms of covid-19 in the community.1 Patients with cough symptoms should take
Mesoblast Limited today announced that it has received clearance from the United States Food and Drug Administration (FDA) for an Investigational New Drug (IND) application to treat patients with acute respiratory distress syndrome (ARDS) caused by coronavirus infection (COVID-19) with intravenous infusions of its allogeneic mesenchymal stem cell (MSC) product candidate Remestemcel-L. Mesoblast Chief Medical
To slow the exponential growth of coronavirus, and lessen the burden on hospitals and healthcare workers, local and state officials have issued sweeping mandates closing non-essential businesses and schools and ordering residents to stay at home. But have these blunt measures started to “flatten the curve” of the virus’ spread? Source USC Schaeffer Data from
The U.S. Food and Drug Administration continues to play a critical role in accelerating medical countermeasures to treat and prevent COVID-19. As part of the response to this pandemic, the agency is taking the lead on a national effort to facilitate the development of, and access to, two investigational therapies derived from human blood. These
The outbreak of COVID-19 caused by SARS-CoV-2 virus has now become a pandemic, but there is currently very little understanding of the antigenicity of the virus. Source Science A recent study has shown that CR3022 can also bind to the RBD of SARS-CoV-2 . This finding provides an opportunity to uncover a cross-reactive epitope. Therefore
